Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by wildbird1on Mar 28, 2019 8:50am
61 Views
Post# 29546872

RE:Can we all please relax about the bloody PP.

RE:Can we all please relax about the bloody PP.Thank's Nailbiter1...
It does corroborate what was said in the CC presentation (Nov 2018).

https://Plus.google.com/+WeedWarrior/posts/PH11vherjts

GEN said (QUOTE) ''We have tied in with a specialist on investment Banking Group and the specialist investment Banking group is behind us and we're beginning to date the story out to obviously much larger investors. I can tell you that at this point we are actually getting very good reception ''(END of QUOTE).


Nailbiter1 wrote:
Email received from Tripp Yesterday.

Hello James.
What was the opening date for the .05 cent PP offering?
Thanks.

------------------------------------------- REPLY

As usual, a small group of guys are off on a tangent.
The PP was launched in mid Feb when the share price was $0.05\0.06. It was filled within days. Tranche #2 was launched right after because there was so much demand and the new 5-day VWAP put the pricing at $0.08. So, share price still low.
The surge in share price is precisely because we have kept on marketing the company to the mostly new investors. It is their interest that has generated the momentum.
The deals have been long filled. It is the paperwork that has taken time.
James R Howard-Tripp,
Chairman and CEO,
GeneNews Ltd.


Bullboard Posts